US Broker Ratings

NovoCure Limited (NVCR) Stock Analysis: Exploring a 56% Upside Potential with Expanding Oncology Innovations

NovoCure Limited (NASDAQ: NVCR) stands at the forefront of medical innovation in the healthcare sector, particularly in the field of oncology. With its specialization in the development and commercialization of..

Guardian Pharmacy Services, Inc (GRDN) Stock Analysis: Healthcare Innovator with 18% Upside Potential

Guardian Pharmacy Services, Inc. (NASDAQ: GRDN) stands as a significant player in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $2.52 billion, this..

SS Innovations International (SSII) Stock Analysis: Exploring an 86.67% Upside Potential in the Surgical Robotics Arena

SS Innovations International, Inc. (NASDAQ: SSII), a burgeoning player in the healthcare sector, operates within the medical devices industry with a laser focus on surgical robotics. Based in Gurugram, India,..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring an 84% Potential Upside in the Biotech Arena

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has carved a niche in the biotechnology sector with its focus on rare and ultra-rare genetic diseases. For investors seeking opportunities in the healthcare industry,..

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: A Biotech Bet with a 137.70% Revenue Growth

Agios Pharmaceuticals, Inc. (AGIO), a dynamic player in the healthcare sector, is grabbing investor attention with its impressive revenue growth of 137.70%. As a biotechnology company headquartered in Cambridge, Massachusetts,..

Privia Health Group (PRVA) Investor Outlook: 20.86% Upside Potential and Strong Buy Ratings

Privia Health Group, Inc. (NASDAQ: PRVA) stands out in the healthcare sector with its innovative approach to physician enablement and impressive growth metrics. For investors seeking opportunities in the health..

Arrowhead Pharmaceuticals (ARWR): Investor Outlook on Biotech’s 34% Upside Potential

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a burgeoning player in the biotechnology sector, presents an intriguing opportunity for investors with its promising pipeline and significant upside potential. Currently trading at $71.65,..

Clover Health Investments, Corp (CLOV): A Closer Look at its 62% Revenue Growth and Future Prospects

Clover Health Investments, Corp (NASDAQ: CLOV), a significant player in the U.S. healthcare plans sector, has captured investor attention with an impressive 62% revenue growth. As a provider of Medicare..

HUTCHMED (China) Limited (HCM) Stock Analysis: Nearly 100% Potential Upside According to Analyst Ratings

HUTCHMED (China) Limited (NASDAQ: HCM), a prominent player in the healthcare sector specializing in drug manufacturing, is making waves in the investment community with a potential upside of nearly 100%..

BioCryst Pharmaceuticals (BCRX): Investor Outlook on a Biotech with 130% Potential Upside

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), a prominent player in the healthcare sector, is capturing the attention of investors with its robust pipeline and promising market potential. Based in Durham, North..

Tarsus Pharmaceuticals (TARS) Stock Analysis: Exploring a 68% Upside Potential in the Biotech Sector

Tarsus Pharmaceuticals, Inc. (TARS), a promising player in the biotechnology industry with a special focus on eye care, has been making waves with its impressive growth trajectory and robust pipeline...

GeneDx Holdings Corp. (WGS) Stock Analysis: A 34.84% Potential Upside in the Healthcare Sector

GeneDx Holdings Corp. (NASDAQ: WGS) is making waves in the healthcare sector with its focus on providing cutting-edge genetic testing services. Based in Stamford, Connecticut, the company has carved out..

Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 33.91% Upside Potential Amid Strong Revenue Growth

Investors looking for promising opportunities in the healthcare sector should consider Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company with a focus on central nervous system (CNS) diseases. With a..

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Exploring a 16.78% Potential Upside in the Medical Devices Sector

LeMaitre Vascular, Inc. (NASDAQ: LMAT), a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry, is capturing investor attention with its promising growth prospects. Headquartered..

Harmony Biosciences Holdings (HRMY) Stock Analysis: Unveiling a 34% Upside Potential in the Biotech Sector

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) stands as a noteworthy player in the healthcare sector, specifically within the biotechnology industry. With a market capitalization of $1.94 billion, this commercial-stage pharmaceutical..

Ligand Pharmaceuticals (LGND) Stock Analysis: A Biotech Gem with a 5.89% Upside

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has been a standout player in the biotechnology sector, offering a compelling investment case for those with an eye on healthcare innovations. With a market..

Progyny, Inc. (PGNY) Stock Report: Analyzing the Healthcare Innovator’s Potential Amidst Robust Analyst Ratings

Progyny, Inc. (NASDAQ: PGNY), a prominent player in the healthcare plans sector, continues to garner attention from investors with its innovative approach to fertility and family building benefits. With a..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: Navigating High Potential in the Biotechnology Sector

Apogee Therapeutics, Inc. (NASDAQ: APGE), a burgeoning name in the biotechnology sector, has captured the attention of investors with its innovative approach to tackling prevalent inflammatory and immunology conditions. With..

Catalyst Pharmaceuticals (CPRX) Stock Analysis: Steady Growth Amidst Stable Valuation Metrics

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) stands as a noteworthy player within the biotechnology industry, specializing in developing and commercializing treatments for rare diseases. Headquartered in Coral Gables, Florida, the company..

Scholar Rock Holding Corporation (SRRK): Investor Outlook with a Promising 17.08% Upside

Scholar Rock Holding Corporation (NASDAQ: SRRK), a biopharmaceutical innovator focused on treating rare neuromuscular diseases, presents an intriguing opportunity for investors, particularly with a potential upside of 17.08%. As a..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds